RVMD Q1 2022 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-25.2% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$58M-764.7% margin

Net Income

-$58M-760.7% margin

EPS (Diluted)

$-0.77

QoQ Revenue Growth

-19.9%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$57M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$683M

Total Liabilities

$132M

Stockholders' Equity

$551M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$10M	-25.2%
Gross Profit	$8M	$10M	-25.2%
Operating Income	-$58M	-$37M	-55.0%
Net Income	-$58M	-$37M	-55.1%

Revenue Segments

Collaboration Revenue

$8M100%